Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors [Seeking Alpha]
Sutro Biopharma, Inc. (STRO)
Last sutro biopharma, inc. earnings: 11/8 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
The company generated $3.4bn in revenues in 2023, with a core consolidated net profit of $830m. Ipsen typically acquires relatively de-risked drug candidates in later stage clinical studies, but last week announced a deal with Sutro Biopharma, Inc. to develop a pre-clinical antibody drug candidate. The deal pays $90m to Sutro - which has an ADC of its own in a registrational study in ovarian cancer. The deal seems to suit both parties, who have intriguing exposure to an explosive ADC market in oncology. Ipsen offers a more de-risked opportunity, Sutro explosive growth potential with a higher level of risk. Investment Overview Ipsen S.A. ( OTCPK:IPSEY , IPSEF) is a Paris, France-headquartered Pharmaceutical company focused on oncology, rare disease and neuroscience. The company's business is built upon partnering with other biotech and pharma companies developing new drugs. According to Ipsen's website: Since 2020, Ipsen has brought in over 20-best- or first-in class progr
Show less
Read more
Impact Snapshot
Event Time:
STRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STRO alerts
High impacting Sutro Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
STRO
News
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock, down previously from $12.00.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.MarketBeat
- Sutro Biopharma, Inc. (NASDAQ: STRO) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.MarketBeat
STRO
Earnings
- 11/13/23 - Miss
STRO
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/26/24 - Form DEFA14A
- STRO's page on the SEC website